Researchers consider the data encouraging, though questions linger about the cognition results. Did regulators mess up the randomization of this trial?
Analyzing Phase 2 trial CSF of an investigational immunotherapy, scientists showed for the first time that treatment mitigates neurotoxic oligomers in patients.
UCB-J hints at early synaptic loss in the hippocampus, but not the cortex. Researchers puzzle over the pattern.
In SPRINT MIND trial, strict control of systolic pressure slashed MCI incidence by almost 20 percent.
Data from the first human study hints the procedure could help deliver drugs to the brain, or even work as a therapy in its own right. A flurry of animal studies presented at AAIC support the idea.